Literature DB >> 31556406

Influence and mechanism of lung cavitation development on antiangiogenic therapy: is cavitation the new caveat?

Lorenzo Calvetti1, Giuseppe Aprile1.   

Abstract

Year:  2019        PMID： 31556406      PMCID： PMC6749118          DOI： 10.21037/tlcr.2019.08.19

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  18 in total

1.  Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.

Authors:  Maxime Ronot; Mohamed Bouattour; Johanna Wassermann; Onorina Bruno; Chantal Dreyer; Béatrice Larroque; Laurent Castera; Valérie Vilgrain; Jacques Belghiti; Eric Raymond; Sandrine Faivre
Journal:  Oncologist       Date:  2014-03-20

Review 2.  Clinical advances in the development of novel VEGFR2 inhibitors.

Authors:  Caterina Fontanella; Elena Ongaro; Silvia Bolzonello; Michela Guardascione; Gianpiero Fasola; Giuseppe Aprile
Journal:  Ann Transl Med       Date:  2014-12

3.  Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.

Authors:  Xichun Hu; Jian Zhang; Binghe Xu; Zefei Jiang; Joseph Ragaz; Zhongsheng Tong; Qingyuan Zhang; Xiaojia Wang; Jifeng Feng; Danmei Pang; Minhao Fan; Jin Li; Biyun Wang; Zhonghua Wang; Qunling Zhang; Si Sun; Chunmei Liao
Journal:  Int J Cancer       Date:  2014-03-20       Impact factor: 7.396

4.  Glycolytic phenotype and AMP kinase modify the pathologic response of tumor xenografts to VEGF neutralization.

Authors:  Giorgia Nardo; Elena Favaro; Matteo Curtarello; Lidia Moserle; Elisabetta Zulato; Luca Persano; Elisabetta Rossi; Giovanni Esposito; Marika Crescenzi; Oriol Casanovas; Ulrike Sattler; Wolfgang Mueller-Klieser; Barbara Biesalski; Oliver Thews; Rossella Canese; Egidio Iorio; Paola Zanovello; Alberto Amadori; Stefano Indraccolo
Journal:  Cancer Res       Date:  2011-05-05       Impact factor: 12.701

5.  Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors.

Authors:  Mizuki Nishino; Stephanie Cardarella; Suzanne E Dahlberg; David M Jackman; Nikhil H Ramaiya; Hiroto Hatabu; Michael S Rabin; Pasi A Jänne; Bruce E Johnson
Journal:  Lung Cancer       Date:  2012-12-14       Impact factor: 5.705

6.  Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies.

Authors:  Jin Li; Xinmin Zhao; Lei Chen; Haiyi Guo; Fangfang Lv; Ka Jia; Ke Yv; Fengqing Wang; Chuan Li; Jun Qian; Chunlei Zheng; Yunxia Zuo
Journal:  BMC Cancer       Date:  2010-10-05       Impact factor: 4.430

7.  Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer.

Authors:  Simon J Crabb; Demetris Patsios; Eric Sauerbrei; Peter M Ellis; Andrew Arnold; Glenwood Goss; Natasha B Leighl; Frances A Shepherd; Jean Powers; Lesley Seymour; Scott A Laurie
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

8.  Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial.

Authors:  Jin Li; Shukui Qin; Jianming Xu; Weijian Guo; Jianping Xiong; Yuxian Bai; Guoping Sun; Yan Yang; Liwei Wang; Nong Xu; Ying Cheng; Zhehai Wang; Leizhen Zheng; Min Tao; Xiaodong Zhu; Dongmei Ji; Xin Liu; Hao Yu
Journal:  J Clin Oncol       Date:  2013-08-05       Impact factor: 44.544

9.  Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer.

Authors:  Edith M Marom; Carlos H Martinez; Mylene T Truong; Xiudong Lei; Bradley S Sabloff; Reginald F Munden; Gregory W Gladish; Roy S Herbst; Rodolfo C Morice; David J Stewart; Carlos A Jimenez; George R Blumenschein; Amir Onn
Journal:  J Thorac Oncol       Date:  2008-04       Impact factor: 15.609

10.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321
View more
  2 in total

Review 1.  Tumor vessel normalization and immunotherapy in gastric cancer.

Authors:  Xianzhe Yu; Shan He; Jian Shen; Qiushi Huang; Peng Yang; Lin Huang; Dan Pu; Li Wang; Lu Li; Jinghua Liu; Zelong Liu; Lingling Zhu
Journal:  Ther Adv Med Oncol       Date:  2022-07-18       Impact factor: 5.485

2.  Cavity development: a potential biomarker for antiangiogenesis agents.

Authors:  Man Jiang; Xiaochun Zhang
Journal:  Transl Lung Cancer Res       Date:  2020-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.